Lubrizol is to invest $10m to expand fermentation production capacity fivefold at its manufacturing facility in Gavà, Spain.
Gavà is a key site for its Life Science Beauty business and was formerly the Lipotec headquarters after Lubrizol acquired it in 2012.
The US company said the investment reflects a commitment to advancing sustainable innovation through biotechnology.
“By expanding our fermentation capacity, we are not only supporting the growth of high-performance active ingredients but also reinforcing our role as a strategic partner in delivering science-backed, environmentally responsible solutions,” said Bernardo Medeiros, Vice President, Lubrizol Life Sciences.
Lubrizol has been a pioneer in biotechnology since 2001, building a robust, science-driven platform that integrates advanced fermentation and bioprocessing technologies.
Its biotech platform is engineered for sustainability from the ground up, with processes designed to avoid biodiversity loss and minimize environmental impact while ensuring batch-to-batch consistency and optimal performance.
Lubrizol's biotechnology approach includes the use of GMO-free, non-pathogenic microorganisms, sourcing strains without harvesting from nature, and relying on renewable carbon sources.
The production process is designed to generate minimal waste and deliver ingredients with a biodegradable, non-toxic profile.
Many of these ingredients have been approved according to COSMOS standards, further supporting Lubrizol’s commitment to transparency and environmental responsibility.
“The increased fermentation capacity positions Lubrizol for continued growth and expanded capabilities, while enhancing manufacturing flexibility — enabling the company to better adapt to both global and regional needs and deliver innovations that meet consumer expectations,” added Medeiros.
